drugset
drugset / Trial / NCT01395927

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

NCT01395927 ↗

Phase 1 Completed 14 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate blood levels of canagliflozin in healthy volunteers before and after the administration of multiple-doses of rifampin.

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject Rifampin Small molecule 300 mg Oral

Indications

No indication recorded.